Regulations

International Collaboration on Cosmetics Safety Names 2026 Board of Directors

L’Oréal, Procter & Gamble, Kenvue and Cosmetics Alliance Canada are represented on the board.

The International Collaboration on Cosmetics Safety (ICCS) appointed its 2026 Board officers. The newly-elected leadership reflects ICCS’ continued commitment to advancing approaches in cosmetics safety, it contends.

The following were elected to serve as the officers for the 2026 Board of directors:

Chair: Stéphane Dhalluin, Ph.D., DABT, global head, human & environmental safety evaluation, L’Oréal

Vice Chair: Darren Praznik, president & CEO, Cosmetics Alliance Canada

Secretary: Heike Scheffler, Ph.D., safety advocacy and regulatory toxicology director, global product stewardship beauty and oral care, Procter & Gamble

Treasurer: Michael Southall, Ph.D., senior director, head of global toxicology and clinical safety, medical clinical & safety sciences, Kenvue

Executive Commentary

“I am thrilled to continue working with an outstanding group of officers whose leadership and dedication are essential to advancing the ICCS mission,” said Erin Hill, president and CEO, ICCS. “As the scientific and regulatory landscape continues to evolve, this Board brings the experience, perspective, and collaborative spirit needed to accelerate progress toward global adoption of animal-free safety science.”

“I am profoundly honored to be re-elected by my peers as Chair of the ICCS Board of Directors,” said Stéphane Dhalluin, Ph.D., DABT, “Building on the momentum of a highly impactful 2025—a year defined by robust achievements and the delivery of concrete scientific frameworks—our mission is clearer than ever. By leveraging our unique global, multi-stakeholder collaboration, we remain dedicated to bridging the gap between innovation and regulation. Together, we are ensuring that cutting-edge, animal-free science becomes the universal standard for protecting human and environmental health.”

Recent Achievements

In 2025, ICCS delivered tangible scientific and regulatory progress, including the release of a Best Practice Guidance document, the development of new methodologies supporting next generation risk assessment and extensive engagement with regulators and scientists worldwide.

Keep Up With Our Content. Subscribe To Happi Newsletters